Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARE study of obeticholic acid in pediatric biliary atresia
NL-OMON53035Phase 2Withdrawn
- Sponsor
- Intercept Pharmaceuticals
- Start
- Aug 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of obeticholic acid in biliary atresia, sponsored by Intercept Pharmaceuticals. Primary endpoints: Safety and tolerability and Pharmacokinetics of obeticholic acid and conjugates. Planned start Aug 2015; status: withdrawn.
02
Drugs
obeticholic acid
03
Conditions
biliary atresia
Beyond the preview
Go deeper on NL-OMON53035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53035.